RFA Plus Chemo Associated with Improved Survival in Unresectable Colorectal CA Liver Metastases

RFA Plus Chemo Associated with Improved Survival in Unresectable Colorectal CA Liver Metastases
RFA Plus Chemo Associated with Improved Survival in Unresectable Colorectal CA Liver Metastases

CHICAGO–Radiofrequency ablation in combination with systemic chemotherapy was associated with improved long-term overall survival compared with chemotherapy alone in patients with unresectable colorectal cancer liver metastases, research presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, have shown.

For the EORTC Intergroup CLOCC study, researchers enrolled 119 patients with unresectable colorectal cancer liver metastases with up to nine lesions and without extrahepatic disease and randomly assigned them to receive 6 months of FOLFOX with or without bevacizumab or radiofrequency ablation plus chemotherapy.

Results showed that median progression-free survival was 9.92 months (95% CI: 9.07,12.85) for systemic treatment versus 16.82 months (95% CI: 11.01,21.88) for combination therapy (HR: 0.57; 95% CI: 0.38,0.85; P=0.005).

Researchers found that median overall survival was 45.6 months (95% CI: 30.3,67.8) in the radiofrequency ablation plus chemotherapy arm versus 40.5 months (95% CI: 27.5,47.7) in the chemotherapy alone arm (HR: 0.58; 95% CI: 0.38,0.88; P=0.010).

“Despite the limitations in this trial due to reduced sample size, this encourages the use of ablative technique as a treatment modality in patients with unresectable colorectal liver metastases,” said Theo Ruers, MD, PhD, professor of surgical oncology at the Netherlands Cancer Institute in the Netherlands.

The study also showed that 49 patients in the chemotherapy arm died as a result of progressive disease compared with 35 patients in the combined treatment arm. A total of 92 deaths were reported.

“In these patients, complete treatment of all liver lesions should be aimed for, which should be discussed in a multidisciplinary team,” Dr. Ruers concluded.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs